Belkin Re-introduces InvisiGlass: Reliable Screen Protection, Now Made With Recycled Glass
9.9.2024 22:38:00 CEST | Business Wire | Press release
The new screen protectors incorporate an impressive 60% post-industrial recycled (PIR) materials1
Belkin, a leading consumer electronics brand for 40 years, today announced its reimagined InvisiGlass screen protection collection, made with certified recycled glass. The InvisiGlass screen protection collection is now available on belkin.com for iPhone 16, iPhone 16 Plus, iPhone 16 Pro, and iPhone 16 Pro Max.
Belkin InvisiGlass is made with glass materials that are collected and recycled during the manufacturing process, certified by the Global Recycled Standard (GRS), and thoroughly tested to ensure the premium quality, durability, reliability and clarity that the brand name is known for.
Fortified with ion-exchange technology, InvisiGlass screen protectors are 62%2 more durable than tempered glass screen protectors without adding thickness or weight to provide best-in-class protection while maintaining the device’s natural look and feel.
The ScreenForce™ InvisiGlass collection includes:
- InvisiGlass – $29.99 USD – the new InvisiGlass is an upgrade to the original InvisiGlass Ultra material introduced in 2017. The new version is enhanced with recycled glass while still smooth to the touch and ultra-thin, preserving touchscreen sensitivity.
- InvisiGlass Blue Light Filter – $34.99 USD – incorporates industry-leading blue light reduction technology by Eyesafe to filter out 60% of blue light3. It is designed to support eye comfort for more enjoyable screen time, whether working, reading, or streaming.
- InvisiGlass Privacy – $34.99 USD – engineered with an added privacy filter to keep emails, webpages, texts and photos protected from prying eyes. It is the ideal solution for working on sensitive documents, banking online, or simply browsing the web or social media.
Belkin InvisiGlass Screen Protectors come in 100% recycled packaging4 using paper certified by the Forest Stewardship Council. The package contains a cleaning cloth, dust removal sticker to prevent air bubbles, and patented Easy Align tray for flawless alignment and fool-proof application.
For more information on Belkin InvisiGlass, see here: www.belkin.com/screenforce/sustainability
Pricing and Availability
The Belkin InvisiGlass Screen Protector collection for the new iPhone 16 lineup is available on belkin.com today for $29.99 – $34.99 USD and coming soon to major retailers worldwide.
Media kit is available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
_________________________
1 Glass is made with a minimum of 60% post-industrial recycled glass and has been certified through GRS.
2 Based on internal tests, screen protectors can withstand up to 62% more force on average compared to conventional tempered glass screen protectors.
3 435-440 nm
4 Recycled plastic components include Easy Align tray, support tray, top protective film, and protective bags.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909753989/en/
Contacts
Media Contact
Media Contact
Jen Wei
VP of Global Communications and Corporate Development
comms@belkin.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom